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ABSTRACT
Rationale: While recent studies show that maternal use of snus during pregnancy is increasing, the
potential effects on infant birth size is less investigated, with conflicting results.
Objectives: We aimed to determine if maternal use of snus during pregnancy influences the infant
anthropometric and proportional size measures at birth.
Methods: In 2313 mother–child pairs from the population-based, mother–child birth cohort
PreventADALL (Preventing Atopic Dermatitis and ALLergies) in Norway and Sweden, we assessed
nicotine exposure by electronic questionnaire(s) at 18 and 34 weeks of pregnancy, and anthropometric
measurements at birth. Associations between snus exposure and birth size outcomes were analysed by
general linear regression.
Results: Birthweight was not significantly different in infants exposed to snus in general, and up to
18 weeks of pregnancy in particular, when adjusting for relevant confounders including maternal age,
gestational age at birth, pre-pregnancy body mass index, parity, fetal sex and maternal gestational weight
gain up to 18 weeks. We found no significant effect of snus use on the other anthropometric or
proportional size measures in multivariable linear regression models. Most women stopped snus use in
early pregnancy.
Conclusion: Exposure to snus use in early pregnancy, with most women stopping when knowing about
their pregnancy, was not associated with birth size. We were unable to conclude on effects of continued
snus use during pregnancy because of lack of exposure in our cohort.
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Snus use in pregnancy, reported by 7.1% of 2313 women, was not associated with infant birth
size. As most women stopped snus use by 6 weeks gestational age, it was not possible to assess
potential birth size effects of persistent use during pregnancy. http://bit.ly/2IG8Vnk
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SNUS AND INFANT BIRTH SIZE
Introduction
Smoking during pregnancy is well established as one of the most modifiable risk factors for adverse
pregnancy and infant related health effects [1], with effects related to infant birth size including increased
risk of low birthweight, length and head circumference [2, 3], ponderal index [3] and being small for
gestational age (SGA) [4–6]. Nonlinear decrease in mean adjusted birthweight has been observed with
increasing number of cigarettes smoked per day during pregnancy [7, 8]. Tobacco exposure may influence
fetal growth throughout pregnancy, with small but significant reductions in head size and femur length in
the first trimester, reduced growth after the first trimester [9] and selective reduction in abdominal
circumference and muscle mass in fetuses exposed in the last trimester [10]. However, it is unclear
whether these findings may be extended to smokeless tobacco.
The use of snus, a smokeless tobacco product also known as moist snuff, and other smokeless nicotine
products such as electronic cigarettes have increased in recent years [11, 12], paralleling decreased smoking
rates among young women in many countries [13]. A similar increased use of snus in women of
reproductive age in Norway and Sweden [12, 14] is also shown during pregnancy [14, 15]. We recently
showed in the Preventing Atopic Dermatitis and Allergies in Children (PreventADALL) study that 11.3%
of pregnant women reported use of any tobacco or nicotine products by 34 weeks of pregnancy; most
commonly as snus only in 6.5%, followed by cigarette smoking only in 4.1% and dual smoking and snus
in <1%. Most women stopped snus use or cigarette smoking early in pregnancy, usually within pregnancy
week six [16]. Nicotine from snus readily crosses the placenta into the fetal compartments and, together
with its metabolites such as cotinine, concentrates in fetal blood, urine, meconium and amniotic fluid [17, 18].
Despite substantial documentation in animal models showing adverse effects in the offspring of nicotine
exposure by the pregnant female, there are few studies to verify these findings in humans [19, 20].
Exposure to snus during pregnancy increased the risk of preterm birth [21], stillbirth [22, 23], oral cleft
malformation [24] and neonatal apnoea [25] in Swedish Medical Birth Register studies, while altered
infant heart rate variability was observed in a prospective observational study [26]. While a study from
India showed an average of 87 g reduced birthweight (adjusted for gestational age) in infants born to
women who used smokeless tobacco regularly in pregnancy [27], no significant effect of snus use was
observed on birthweight in the Swedish registry study [28]. Thus, the effect of snus on birthweight is
unclear, nor are we aware of studies assessing potential effects of snus use on other infant size measures at
birth [19].
Therefore, we aimed to determine if maternal use of snus in pregnancy might affect infant anthropometric
and proportional size measures at birth.
Subjects and methods
Study design
This study is based on the large population-based, prospective mother–child birth cohort PreventADALL [29],
enrolling 2697 women with 2701 pregnancies and their 2397 infants born at a gestational age of
⩾35.0 weeks without serious neonatal disease. The main objectives of the PreventADALL study are to
determine whether primary prevention of allergic diseases is possible through a 2×2 factorially designed,
randomised trial of two interventions. Additionally, early life exposures and factors involved in allergic
diseases and noncommunicable diseases are assessed. Pregnant females were recruited at the routine
ultrasound screening at second trimester between gestational weeks 16 and 22, in hospitals from the
general, nonselected population from the greater area of Oslo and southeast Norway as well as from the
Stockholm area in Sweden between December 2014 and October 2016 [29]. Details of recruitment,
inclusion and exclusion criteria are given in the supplementary material.
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The present study included all 2313 mother–child pairs with available exposure data of any type of
nicotine or tobacco product from electronic questionnaires at 18 and/or 34 weeks of pregnancy and whose
included singleton newborn babies had anthropometric measurements performed at birth (supplementary
figure S1).
Maternal written consent was obtained upon primary enrolment and signed by both parents at newborn
inclusion. The PreventADALL study was approved by the regional committees for medical and health
research ethics in South-Eastern Norway (2014/518) and in Sweden (2014/2242-31/4).
Subjects
Baseline characteristics among the included and the excluded study participants were similar, except for
marital status, previous smoking history and gestational age at birth as shown in supplementary table S1.
Methods
From electronic questionnaires completed by the women at 18 and 34 weeks of pregnancy, we collected
detailed information about snus, cigarette smoking, nicotine replacement therapy (NRT) or electronic
cigarettes: never, ever, prior to pregnancy, and during pregnancy up to 18 weeks and from 18 weeks to
34 weeks [16]. Background characteristics and history of previous and present pregnancies were obtained
from the 18-week questionnaire and a brief interview at enrolment. Whether the women reported the
ultrasound-corrected gestational age or calculated gestational age from their last menstrual period is not
known. Study personnel measured maternal weight and height at the 18-week inclusion visit.
Pre-pregnancy weight was obtained by self-report rather than by objective measures.
Dedicated trained study personnel using a non-elastic measuring tape performed infant anthropometric
measures within the first 24 h after delivery. We report the mean of two left upper arm circumference
measures midway between the acromial and olecranon process, and the mean of three thoracic and
abdominal circumference measures performed at end-expiration when possible. For the thoracic
circumference measures we placed the lower part of the measuring tape in line with the most caudal part
of the xyphoid process. For the abdominal circumference measures the lower end of the measuring tape
was placed in line with the cranial part of the umbilicus. All values were recorded in centimetres with one
decimal, and mean values were calculated and rounded when appropriate. Background for the methods
used is described in the supplementary material. Birthweight, length (crown–heel) and head circumference
as well as placenta weight was collected from the hospital records. Placenta was weighed and recorded by
the midwives within 30 min of delivery according to hospital guidelines.
Outcomes, exposures and covariates
The main outcome was birthweight (in grams). Secondary anthropometric outcomes were birth length,
head circumference, thoracic circumference, abdominal circumference and left mid upper arm
circumference (all in centimetres), while the ratios of abdominal circumference to head circumference,
thoracic circumference to head circumference, thoracic circumference to abdominal circumference and
finally birthweight to placenta weight were proportional size outcomes.
The main exposure variables were based on any use of snus and/or smoke in pregnancy categorised into
never in pregnancy (“never”), snus alone in pregnancy (“snus only”) and smoking including dual snus users
in pregnancy (“smoke/dual”). To differentiate between early and late snus exposure, we also separated the
snus only group into “snus only 18 weeks” and “snus only 34 weeks”. Women who reported ever-use of snus
and/or smoking before pregnancy were included in the never group representing never-use during pregnancy.
As only four women reported using NRT or electronic cigarettes, of whom three stopped when recognising
pregnancy, they were included in the analyses based upon their use of snus and cigarette smoking.
Potential covariates were based upon factors previously shown to be associated with snus use in pregnancy [16]
including maternal age, marital status, previous smoking history, in utero smoking exposure of the index
women and living area. Additionally, we included factors possibly associated with birth size of the baby
such as maternal education, pre-pregnancy body mass index (BMI), parity, fetal sex and gestational age at
delivery (days). Further, as smoking cessation during pregnancy may cause weight gain [30, 31], we
performed sensitivity analyses including adjustment for maternal gestational weight gain from
pre-pregnancy to 18 weeks of pregnancy. The gestational age was based on femur length obtained at the
routine second trimester ultrasound, as described previously [29].
Statistical analysis
Categorical variables are presented as numbers and percentages, and continuous variables as means with
standard deviation or 95% confidence intervals. Differences between categorical variables were analysed by
Chi-squared test and numerical data by one-way ANOVA tests.
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Associations between snus exposure and birth size outcomes were analysed using univariable and
multivariable linear regression models with the birth outcomes as dependent variable and snus use as
independent variable. The group of never snus users were defined as the reference group. In the
multivariable models we included all covariates that were known potential confounders associated with
snus use from our previous study [16] and the literature in general. Significant covariates with a p-value
<0.05 were kept in the final models, as appropriate for each outcome, with details given in supplementary
table S3. Sensitivity analyses including adjustment for maternal gestational weight gain from pre-pregnancy
to 18 weeks of pregnancy were performed in case of significant associations between snus use and the
respective birth outcome.
The significance level was set to 5%. Because of low numbers of missing data we performed complete case
analysis only. All analyses were performed using SPSS Statistics (version 25; IBM, Chicago, IL, USA).
Results
Most women (89.1%) reported never-use of tobacco products during pregnancy, while 150 (6.5%) reported
snus only and 102 (4.4%) reported cigarette smoking, including 15 (0.6%) dual users. Up to 18 weeks of
pregnancy 138 (6.0%) women used snus only at some time or current, and 12 (0.6%) up to 34 weeks. The
majority (>90%) of the snus and smoking/dual-using women stopped within pregnancy week six.
Exposure to nicotine products was similar in term and preterm infants, as described in detail in the
supplementary material and table S2.
The exposure groups never, snus only and smoke/dual differed significantly from each other with respect
to gestational age at birth, maternal age, maternal gestational weight gain, parity and socioeconomic
factors, as listed in table 1.
Unadjusted analyses showed no significant difference in birthweight among the women who used snus
only compared to never and smoke/dual users (table 2). We observed significantly higher birthweight in
infants exposed to snus only up to 18 weeks (table 3) after adjusting for parity, gestational age at birth,
fetal sex, pre-pregnancy BMI and maternal age in multivariable regression analyses. However, after
adjusting for maternal gestational weight gain (from pre-pregnancy to gestational week 18), the
associations were no longer statistically significant in sensitivity analyses (table 3). We found no significant
interaction between gestational weight gain and the tobacco exposure groups.
For the “snus up to 34 weeks” group, there was a nonsignificant trend of decreased birthweight.
The only other anthropometric measure with significant associations to snus exposure in unadjusted (table 2)
and adjusted regression analyses (supplementary table S4) was head circumference. However, after
adjusting for maternal gestational weight gain (from pre-pregnancy to gestational week 18) in sensitivity
analyses, the association was no longer significant. We found no other significant associations between
snus exposure in the univariable or multivariable regression analyses on anthropometric (supplementary
table S4) or proportional size outcomes (supplementary table S5).
Discussion
In our cohort, in which 90% of the women stopped snus use at recognised pregnancy, snus exposure was
not significantly associated with birthweight or other anthropometric or proportional size measures.
To our knowledge, this is the first prospective mother–child cohort study showing that the use of snus in
pregnancy was not associated with infant birth size. Our results are supported by registry studies showing
that women who quit snus early in pregnancy had the same risk of SGA or low birthweight of the baby as
non-snus users [28, 32]. This is in contrast to an Indian cohort study of 1217 women interviewed during
months 3–7 of pregnancy at house-to-house visits showing an average of 105 g lower birthweight among
the 17% reporting daily use of chewable tobacco for ⩾6 months [27]. However, there are important
differences between the studies in regards to types of smokeless tobacco products, prevalence of exposures
as well as probable cultural and sociodemographic differences. In view of the presumably low total in utero
nicotine exposure in our study, with most women stopping in early pregnancy, our findings are in line
with other studies showing that early cessation attenuates the effects of snus [32] or smoking [7].
The apparently higher birthweight in infants born to mothers using snus up to 18 weeks of pregnancy
only, before adjusting for maternal weight gain, is in contrast to registry studies from Sweden, where
nonsignificant reductions in birthweight were observed in sibling analyses [28]. However, sensitivity
analyses showed that the significantly higher maternal gestational weight gain in those stopping snus use
compared to non-users largely explained the difference in the model not adjusting for weight gain. We are
unaware of studies including maternal gestational weight gain in their adjusted models, but propose that
maternal gestational weight gain should be included in analyses exploring potential effects of nicotine
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TABLE 1 Background characteristics of the study population (n=2313) stratified by tobacco
exposure during pregnancy
Subjects Tobacco exposure during pregnancy#
Never Snus only Smoke/dual p-value
Subjects 2313 2061 (89.1) 150 (6.5) 102 (4.4)
Fetal sex male 1097 (53.0) 73 (48.7) 50 (48.5) 0.37
Gestational age at birth 2274
Weeks 39.2±1.7 39.6±1.7 38.9±1.7 0.001
Days 274.7±11.6 277.5±11.7 272.0±11.8 0.001
Placenta weight g 1740 656±135.1 679±110.2 643±144.9 0.12
Maternal factors
Age years 2313 32.6±4.1 30.9±3.2 32.0±4.8 <0.001
Pre-pregnancy BMI 2252 23.1±3.6 22.8±3.5 23.9±4.7 0.05
BMI at 18 weeks 2278 24.8±3.6 24.8±3.6 25.8±4.8 0.016
Weight pre-pregnancy kg 2263 65.4±11.1 64.8±11.1 66.4±13.4 0.55
Weight at inclusion kg 2288 70.1±11.1 70.4±11.4 71.6±13.5 0.37
Gestational weight gain up to 18 weeks kg 2259 4.7±3.2 5.4±3.5 5.3±3.8 0.002
Pregnancy history
Current in vitro fertilisation 2300 173 (8.4) 4 (2.7) 0 (0.0) <0.001
Miscarriage(s) <12 weeks 2300 0.08
0 1531 (74.3) 126 (84.0) 73 (70.9)
1 371 (18.0) 15 (10.0) 20 (19.4)
>1 146 (7.1) 9 (6.0) 10 (9.7)
Miscarriage(s)/stillbirths 12–23 weeks 2300 0.006
0 2006 (97.9) 148 (98.7) 96 (94.1)
1 41 (2.0) 2 (1.3) 5 (4.9)
>1 1 (0.0) 0 (0.0) 1 (1.0)
Parity 2150 0.008
0 1124 (59.2) 107 (71.8) 59 (57.8)
1 612 (32.2) 36 (24.2) 29 (28.4)
>1 163 (8.6) 6 (4.0) 14 (13.7)
Sociodemographic factors
Education 2141 <0.001
Preliminary school only 13 (0.7) 1 (0.7) 2 (2.0)
High school only 175 (9.3) 19 (12.8) 25 (24.5)
Higher education <4 years 580 (30.7) 60 (40.5) 42 (41.2)
Higher education ⩾4 years 1122 (59.3) 67 (45.3) 33 (32.4)
Other 1 (0.1) 1 (0.7) 0 (0.0)
Country of origin 2150 0.005
Norway and Sweden 1683 (88.6) 144 (96.6) 87 (85.3)
Rest of the world 216 (11.4) 5 (3.4) 15 (14.7)
Marital status 2150 <0.001
Married 816 (43.0) 39 (26.2) 30 (29.4)
Cohabitants 1037 (54.6) 107 (71.8) 66 (64.7)
Single 30 (1.6) 2 (1.3) 5 (4.9)
Divorced/separated 1 (0.1) 0 (0.0) 0 (0.0)
Other 15 (0.8) 1 (0.7) 1 (1.0)
Living area 2150 0.026
City, densely populated 716 (37.7) 76 (51.0) 42 (41.2)
City, less densely populated 732 (38.5) 52 (34.9) 33 (32.4)
Suburb 311 (16.4) 15 (10.1) 17 (16.7)
Countryside, village 100 (5.3) 5 (3.4) 5 (4.9)
Countryside, outside village 40 (2.1) 1 (0.7) 5 (4.9)
Household income 2150 <0.001
Low 18 (0.9) 3 (2.0) 4 (3.9)
Middle 991 (52.2) 87 (58.4) 72 (70.6)
High 857 (45.1) 57 (38.3) 24 (23.5)
Not reported 33 (1.7) 2 (1.3) 2 (2.0)
Smoking history
Previous smoking 2150 300 (14.6) 75 (50.0) 100 (98.0) <0.001
Continued
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exposure in utero on fetal growth. This is supported by studies showing an increased risk of excess
gestational weight gain from pre-pregnancy to delivery when quitting smoking in pregnancy compared to
non-smokers [30, 31] and substantially lower rate of neonatal birthweight below the 10th percentile [33].
However, we are unaware of studies on maternal gestational weight gain after snus cessation during
pregnancy.
We were unable to conclude on the effects of continuous snus exposure through pregnancy up to
34 weeks, with only 11 subjects in this exposure group. Thus, the potential effect of continued use of snus
throughout pregnancy is still uncertain. We did see a nonsignificant trend of decreased birthweight in this
group, which is in line with the Indian study of smokeless tobacco [27], as well as in conventional [32],
but not in sibling analyses in the Swedish birth registry study [26].
TABLE 1 Continued
Subjects Tobacco exposure during pregnancy#
Never Snus only Smoke/dual p-value
In utero exposure to cigarette smoke 2150 <0.001
No 1463 (77.0) 87 (58.4) 73 (71.6)
Yes 256 (13.5) 29 (19.5) 21 (20.6)
Do not know 180 (9.5) 33 (22.1) 8 (7.8)
Data are presented as n, n (%) or mean±SD, unless otherwise stated. BMI: body mass index. #: includes
four females who answered “yes” to ever-use of other nicotine products (nicotine replacement therapy or
electronic cigarettes); one was a daily user during pregnancy at 18 weeks and three quit when recognising
pregnancy.
TABLE 2 Anthropometric measures and proportional size are given by tobacco exposure
groups for 2313 newborn infants
Subjects Tobacco exposure during pregnancy#
Never Snus only Smoke/dual p-value
Anthropometric
measures
2061 (89.1) 150 (6.5) 102 (4.4)
Birthweight g 2252 3577 (3556–5598) 3662 (3591–3733) 3575 (3472–3678) 0.11
Length cm 2181 50.5 (50.4–50.6) 50.8 (50.4–51.1) 50.4 (49.9–50.9) 0.26
Head circumference cm 2238 35.2 (35.1–35.3) 35.5 (35.3–35.8) 35.3 (34.9–35.6) 0.029
Thoracic
circumference cm
2157 34.0 (33.9–34.1) 34.2 (33.9–34.5) 34.2 (33.7–34.7) 0.30
Abdominal
circumference cm
2156 32.8 (32.7–32.8) 32.9 (32.5–33.3) 32.7 (32.2–33.2) 0.79
Left mid upper arm
circumference cm
2166 11.1 (11.1–11.2) 11.3 (11.2–11.5) 11.2 (11.0–11.4) 0.15
Proportional size
Abdominal/head
circumference
2102 0.94 (0.93–0.94) 0.92 (0.92–0.94) 0.93 (0.91–0.94) 0.45
Thoracic/abdominal
circumference
2151 1.04 (1.037–1.04) 1.04 (1.04–1.05) 1.05 (1.04–1.06) 0.14
Thoracic/head
circumference
2103 0.97 (0.965–0.97) 0.96 (0.96–0.97) 0.97 (0.96–0.98) 0.68
Birthweight/placenta
weight
1729 5.6 (5.5–5.7) 5.5 (5.4–5.7) 5.7 (5.5–6.0) 0.54
Data are presented as n (%), n or mean (95% CI), unless otherwise stated. The reference group “never”
includes all females who did not report use of tobacco or nicotine during pregnancy. The “smoke/dual”
group includes dual smokers and snus users during pregnancy. Most of these subjects (>90%) quit snus
use or smoking by 6 weeks of pregnancy. #: includes four females who answered “yes” to ever-use of
other nicotine products (nicotine replacement therapy or electronic cigarettes); one was a daily user
during pregnancy at 18 weeks and three quit when recognising pregnancy.
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TABLE 3 Linear regression analyses: effect of tobacco exposure during pregnancy on birthweight (grams)
Univariable Multivariable# (1–5) Univariable sensitivity analyses Multivariable sensitivity analyses
(1–6)
Subjects
n
β (95% CI) p-value Subjects
n
β (95% CI) p-value Subjects
n
β (95% CI) p-value Subjects
n
β (95% CI) p-value
Tobacco
exposure
0.085 0.113 0.110 0.550
Never 1772 Ref. 1772 Ref. 1694 Ref. 1694 Ref.
Snus only 143 91.3 (10.1–172.5) 143 78.1 (4.7–151.5) 137 88.8 (5.6–172.0) 137 36.3
(−37.4–110.0)
Smoke/dual 97 −6.5
(−103.9–90.9)
97 11.0
(−76.6–98.6)
90 −5.0
(−106.4–96.4)
90 −20.1
(−109.1–68.9)
Tobacco
exposure
0.120 0.032 0.180 0.250
Never 1772 Ref. 1772 Ref. 1694 Ref. 1694 Ref.
Snus only up to
18 weeks
132 102.0
(17.7–186.3)
132 100.0
(23.9–176.1)
127 96.8 (10.6–183.0) 127 53.8
(−22.6–130.1)
Snus only up to
34 weeks
11 −36.4
(−318.9–246.1)
11 −183.1
(−436.5–70.3)
10 −13.1
(−310.3–284.1)
10 −180.6
(−440.6–79.5)
Smoke/dual 97 −6.5
(−103.9–90.9)
97 10.9
(−76.7–98.4)
90 −5.0
(−106.4–96.4)
90 −20.0
(−108.9–69.0)
The reference group “never” includes all females who did not report use of tobacco or nicotine during pregnancy. The “smoke/dual” group includes dual smokers and snus users during
pregnancy, of whom most quit before 6 weeks of pregnancy. The nonsignificant global p-values for snus-only and smoke/dual indicate that no significant associations were observed with
birthweight. Covariates used in multivariable analyses: 1=parity, 2=gestational age at birth, 3=fetal sex, 4=pre-pregnancy body mass index, 5=maternal age, 6=gestational weight gain up
to 18 weeks of pregnancy. Ref.: reference value. #: the results of the multivariable analyses restricted by the same study population as in the sensitivity analyses without adjusting for
gestational weight gain, were similar in both populations (data not shown).
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To our knowledge, this is the first study to investigate the potential effect of snus exposure in pregnancy
on anthropometric and proportional size measures at birth. Birth size is determined by genetic
predisposition and by the intrauterine environment, including potential unfavourable in utero exposures
affecting fetal growth [34]. While birthweight and length are predictors of lean mass [35], abdominal
circumference may indicate level of fat and/or size of the liver [34], and upper mid arm circumference
predicts muscle mass [36]. Our study with predominantly early transient exposure to snus was not able to
replicate the adverse effects on differential fetal growth by exposure to cigarette smoke [2, 3, 10].
The study is strengthened by the prospective design, specifically designed questionnaires completed at 18
and 34 weeks of pregnancy with detailed information on the use of products containing nicotine during
pregnancy and time of cessation specified by 2-week intervals. The study provides standardised detailed
anthropometric measurements conducted by trained study personnel within the first 24 h after delivery.
The high early pregnancy cessation rates of both snus use and cigarette smoking in this study is clearly
positive for maternal and infant health, but limited our ability to study the effects of persistent use during
pregnancy. Nevertheless, it provides important information for pregnant women who have stopped using
snus or are planning to quit, as well as for health professionals providing their prenatal care, that early
exposure does not seem to affect the birth size of the baby. In addition, detailed information of frequency
of use and number of snus portions and/or cigarettes smoked among those who stopped when recognising
their pregnancies are lacking, thus limiting the possibilities to assess dose–response effects. Our data are
based on self-reports with no objective validation of nicotine or cotinine levels during pregnancy.
Nevertheless, studies have shown that self-reports represent valid markers for tobacco exposure [37, 38].
There is uncertainty regarding the exact pregnancy week of self-reported cessation, as we do not know if
the subjects reported the ultrasound corrected gestational age or the calculated gestational age from the
last menstrual period. If the reported gestational age was the latter, the first two pregnancy weeks
correspond with the last 2 weeks before conception, thus nicotine exposure to the offspring might be
limited. The gestational age was determined based upon the routine ultrasound examination, as described
in the supplementary material, with a potential variation that could not be accounted for in the present
analyses. Additionally, we only adjust for weight gain in the first 18 weeks of pregnancy, since we do not
have weight of the mothers at delivery. However, since most women stopped using snus by pregnancy
week six, one might assume the weight gain effect related to cessation might be in the period up to
18 weeks of pregnancy. Although the participants were recruited from a nonselected general population,
the educational level in our study was higher than in the Norwegian general population [29]. However,
this is unlikely to impact the prevalence of snus use, since we have recently found that educational level is
not associated with snus use during pregnancy [16]. It might affect the choice of lifestyle and diet,
potentially influencing fetal growth. As this is a prospective cohort study, nonparticipation cannot be
associated with the outcome. Therefore, effect estimates of snus use on birth outcomes should not be
biased [39]. Potential covariates such as pre-eclampsia, gestational diabetes or other relevant maternal
diseases that possibly could explain birth size were unavailable at the time of analyses.
Conclusion
Maternal snus use in pregnancy, with most subjects stopping when knowing about their pregnancy, was
not significantly associated with birthweight or anthropometric or proportional size measures of the
newborn infants. Due to low prevalence of snus users up to 34 weeks of gestation, we could not conclude
on potential effects of continued snus exposure in pregnancy on infant birth size.
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